within Pharmacolibrary.Drugs.ATC.M;

model M03AC08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 2.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.00011999999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Fazadinium bromide is a non-depolarizing neuromuscular blocking agent that was used to induce muscle relaxation during surgical procedures or mechanical ventilation. It acts as a competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction. The drug is no longer widely used or approved in most countries due to the development of safer alternatives.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters in healthy adult individuals based on typical ranges for similar non-depolarizing neuromuscular blocking agents; no direct pharmacokinetic publications or sources found.</p><h4>References</h4><ol><li><p>Pastorino, AM (1978). Fluorimetric determination and pharmacokinetic studies of fazadinium bromide in dogs. <i>Arzneimittel-Forschung</i> 28(10) 1728â€“1730. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39568/&quot;>https://pubmed.ncbi.nlm.nih.gov/39568</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M03AC08;
